Neoadjuvant comparisons of aromatase inhibitors and tamoxifen: pretreatment determinants of response and on-treatment effect.

@article{Ellis2003NeoadjuvantCO,
  title={Neoadjuvant comparisons of aromatase inhibitors and tamoxifen: pretreatment determinants of response and on-treatment effect.},
  author={Matthew J. Ellis and Eric Rosen and Holly Dressman and Jeffery Marks},
  journal={The Journal of steroid biochemistry and molecular biology},
  year={2003},
  volume={86 3-5},
  pages={301-7}
}
Adjuvant endocrine therapy reduces the risk of relapse and death from early stage hormone receptor positive breast cancer. However, tamoxifen is only partially effective because of the development of tumor resistance. Aromatase inhibitors (letrozole, anastrozole and exemestane) are also prone to the development of resistance but the pharmacologic action… CONTINUE READING